BrainStorm Cell Therapeutics' (BCLI) NurOwn adult stem cells helped a patient with Lou Gehrig's Disease and myasthenia gravis (MG) show significant improvement in cognition, speech, and muscle power a month after treatment.
After six months, the patient's symptoms had worsened again but improved when he was given another injection of NurOwn.
"The results suggest that repeated therapy may maintain and enhance the clinical benefits of NurOwn cell therapy in neurological diseases," a case report that is being published in "Muscle & Nerve" says.
BrainStorm expects to finalize a Phase IIa clinical trial in H1.
Shares are +5.6%. (PR)